Title:
DEXTRAN-MAGNETIC IRON OXIDE NANOPARTICLE, PREPARATION AND USE IN TREATING CANCER AND AS CONTRAST
Document Type and Number:
WIPO Patent Application WO/2018/098705
Kind Code:
A1
Abstract:
A dextran-magnetic iron oxide nanoparticle, comprising a dextran layer, a magnetic iron oxide nanoparticle and an active drug, the dextran being thinly coated on the outside of the magnetic iron oxide nanoparticle, and the active drug being conjugated to the dextran layer by means of a non-covalent bond; the active drug may be erlotinib, and the dextran-magnetic iron oxide nanoparticle may be used to treat cancer and as contrast.
Inventors:
CHEN CHENG-YU (CN)
AHMED ALI AHMED ATEF (CN)
HSU FEI-TING (CN)
HUANG HSU-SHAN (CN)
AHMED ALI AHMED ATEF (CN)
HSU FEI-TING (CN)
HUANG HSU-SHAN (CN)
Application Number:
PCT/CN2016/108073
Publication Date:
June 07, 2018
Filing Date:
November 30, 2016
Export Citation:
Assignee:
SAGABIO CO LTD (CN)
International Classes:
A61K49/06; A61K49/12; A61P35/00
Domestic Patent References:
| WO2004083902A2 | 2004-09-30 |
Foreign References:
| CN105600832A | 2016-05-25 | |||
| CN102580120A | 2012-07-18 | |||
| CN101698106A | 2010-04-28 |
Other References:
ALI, A.A.A. ET AL.: "Erlotinib-Conjugated Iron Oxide Nanoparticles as a Smart Cancer-Targeted Theranostic Probe for MRI", SCIENTIFIC REPORTS, vol. 6, 11 November 2016 (2016-11-11), pages 1 - 16, XP055606475
Attorney, Agent or Firm:
BEIJING HUI & XIN IP LAW OFFICE (CN)
Download PDF: